Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death - PubMed (original) (raw)

Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death

A B Kulkarni et al. Proc Natl Acad Sci U S A. 1993.

Abstract

To delineate specific developmental roles of transforming growth factor beta 1 (TGF-beta 1) we have disrupted its cognate gene in mouse embryonic stem cells by homologous recombination to generate TGF-beta 1 null mice. These mice do not produce detectable amounts of either TGF-beta 1 RNA or protein. After normal growth for the first 2 weeks they develop a rapid wasting syndrome and die by 3-4 weeks of age. Pathological examination revealed an excessive inflammatory response with massive infiltration of lymphocytes and macrophages in many organs, but primarily in heart and lungs. Many lesions resembled those found in autoimmune disorders, graft-vs.-host disease, or certain viral diseases. This phenotype suggests a prominent role for TGF-beta 1 in homeostatic regulation of immune cell proliferation and extravasation into tissues.

PubMed Disclaimer

Similar articles

• Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated.
  Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, Saffitz JE, Doetschman T. Diebold RJ, et al. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12215-9. doi: 10.1073/pnas.92.26.12215. Proc Natl Acad Sci U S A. 1995. PMID: 8618872 Free PMC article.
• Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype.
  Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB. Geiser AG, et al. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9944-8. doi: 10.1073/pnas.90.21.9944. Proc Natl Acad Sci U S A. 1993. PMID: 8234339 Free PMC article.
• Beta 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-beta 1 null mouse.
  Kobayashi S, Yoshida K, Ward JM, Letterio JJ, Longenecker G, Yaswen L, Mittleman B, Mozes E, Roberts AB, Karlsson S, Kulkarni AB. Kobayashi S, et al. J Immunol. 1999 Oct 1;163(7):4013-9. J Immunol. 1999. PMID: 10491004
• Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease.
  Kulkarni AB, Karlsson S. Kulkarni AB, et al. Am J Pathol. 1993 Jul;143(1):3-9. Am J Pathol. 1993. PMID: 8317552 Free PMC article. Review. No abstract available.
• The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases.
  Prud'homme GJ, Piccirillo CA. Prud'homme GJ, et al. J Autoimmun. 2000 Feb;14(1):23-42. doi: 10.1006/jaut.1999.0339. J Autoimmun. 2000. PMID: 10648114 Review.

Cited by

• TGF-β Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development.
  Li X, Wu Y, Tian T. Li X, et al. Int J Mol Sci. 2022 Nov 20;23(22):14436. doi: 10.3390/ijms232214436. Int J Mol Sci. 2022. PMID: 36430910 Free PMC article. Review.
• The Role of TGFβ Signaling in Squamous Cell Cancer: Lessons from Mouse Models.
  Glick AB. Glick AB. J Skin Cancer. 2012;2012:249063. doi: 10.1155/2012/249063. Epub 2012 Dec 26. J Skin Cancer. 2012. PMID: 23326666 Free PMC article.
• GARP regulates the bioavailability and activation of TGFβ.
  Wang R, Zhu J, Dong X, Shi M, Lu C, Springer TA. Wang R, et al. Mol Biol Cell. 2012 Mar;23(6):1129-39. doi: 10.1091/mbc.E11-12-1018. Epub 2012 Jan 25. Mol Biol Cell. 2012. PMID: 22278742 Free PMC article.
• TGF-β1 secreted by hepatocellular carcinoma induces the expression of the Foxp3 gene and suppresses antitumor immunity in the tumor microenvironment.
  Wang Y, Deng B, Tang W, Liu T, Shen X. Wang Y, et al. Dig Dis Sci. 2013 Jun;58(6):1644-52. doi: 10.1007/s10620-012-2550-4. Epub 2013 Jan 30. Dig Dis Sci. 2013. PMID: 23361571
• Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers.
  Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Amodio V, et al. Cancers (Basel). 2021 May 27;13(11):2638. doi: 10.3390/cancers13112638. Cancers (Basel). 2021. PMID: 34072037 Free PMC article. Review.

References

1. 1. J Clin Immunol. 1992 Mar;12(2):61-74 - PubMed
2. 1. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):421-5 - PubMed
3. 1. Int Immunol. 1992 May;4(5):615-20 - PubMed
4. 1. Lab Invest. 1983 Apr;48(4):419-27 - PubMed
5. 1. Am J Pathol. 1979 Jul;96(1):121-42 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • BioCyc
  • Gene Ontology
  • Mouse Genome Informatics (MGI)